Bristol James Arthur — SEC insider filings

SEC reporting owner CIK 1715153. 21 insider filings on record with FilingPulse; latest filed 2026-09-01.

Transaction summary — filings shown

Covers all 21 filings on record, filed 2020-10-13 to 2026-09-01. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Deciphera Pharmaceuticals, Inc.Director9—10 legs · 52,241 sh · $2,580,21220
Erasca, Inc. (ERAS)Director91 leg · 20,000 sh · $82,800—8
Ernexa Therapeutics Inc. (ERNA)Director3——4

Insider filings — Bristol James Arthur

FiledFormIssuerReported transactionsSource
2026-09-014Ernexa Therapeutics Inc. (ERNA)Grant/award (A): 8,320 (derivative) @ $0 · Grant/award (A): 5,083 (derivative) @ $0EDGAR
2026-06-294Erasca, Inc. (ERAS)Grant/award (A): 29,888 (derivative) @ $0EDGAR
2026-01-054Erasca, Inc. (ERAS)Grant/award (A): 37,762 (derivative) @ $0EDGAR
2025-06-264Erasca, Inc. (ERAS)Grant/award (A): 120,000 (derivative) @ $0EDGAR
2025-02-104Eterna Therapeutics Inc. (ERNA)Grant/award (A): 72,074 (derivative) @ $0EDGAR
2025-01-024Erasca, Inc. (ERAS)Grant/award (A): 45,678 (derivative) @ $0EDGAR
2024-06-214Erasca, Inc. (ERAS)Grant/award (A): 60,000 (derivative) @ $0EDGAR
2024-06-114Deciphera Pharmaceuticals, Inc.Disposition to issuer (D): 22,150 (derivative) · Disposition to issuer (D): 67,494 (derivative) · Disposition to issuer (D): 12,000 (derivative) · Disposition to issuer (D): 9,570 (derivative) · Disposition to issuer (D): 18,500 (derivative) · Disposition to issuer (D): 30,000 (derivative)EDGAR
2024-04-294Eterna Therapeutics Inc. (ERNA)Grant/award (A): 124,525 (derivative) @ $0EDGAR
2024-01-034Erasca, Inc. (ERAS)Grant/award (A): 62,747 (derivative) @ $0EDGAR
2023-06-264Erasca, Inc. (ERAS)Grant/award (A): 60,000 (derivative) @ $0EDGAR
2023-06-234Deciphera Pharmaceuticals, Inc. (DCPH)Grant/award (A): 30,000 (derivative) @ $0EDGAR
2022-12-224Erasca, Inc. (ERAS)Purchase (P): 20,000 @ $4.14EDGAR
2022-06-244Deciphera Pharmaceuticals, Inc. (DCPH)Grant/award (A): 18,500 (derivative) @ $0EDGAR
2022-06-244Erasca, Inc. (ERAS)Grant/award (A): 40,000 (derivative) @ $0EDGAR
2022-01-204Deciphera Pharmaceuticals, Inc. (DCPH)Grant/award (A): 9,570 (derivative) @ $5.22EDGAR
2021-06-254Deciphera Pharmaceuticals, Inc. (DCPH)Grant/award (A): 12,000 (derivative) @ $0EDGAR
2021-04-214Deciphera Pharmaceuticals, Inc. (DCPH)Option exercise (M): 5,300 @ $3.95 · Sale (S): 4,000 @ $46.13 · Sale (S): 1,300 @ $46.66 · Option exercise (M): 1,700 @ $3.95 · Sale (S): 1,700 @ $45.60 · Option exercise (M): 5,300 (derivative) @ $0 · +1 moreEDGAR
2021-04-144Deciphera Pharmaceuticals, Inc. (DCPH)Option exercise (M): 14,700 @ $3.95 · Sale (S): 9,483 @ $43.70 · Sale (S): 5,217 @ $44.09 · Option exercise (M): 14,700 (derivative) @ $0EDGAR
2021-01-204Deciphera Pharmaceuticals, Inc. (DCPH)Option exercise (M): 7,000 @ $3.95 · Sale (S): 6,400 @ $50.21 · Sale (S): 600 @ $51.11 · Option exercise (M): 7,000 (derivative) @ $0EDGAR
2020-10-134Deciphera Pharmaceuticals, Inc. (DCPH)Option exercise (M): 23,541 @ $1.89 · Sale (S): 19,370 @ $53.35 · Sale (S): 3,971 @ $54.53 · Sale (S): 200 @ $55.43 · Option exercise (M): 23,541 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-10-09 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1715153 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs